← All trials
NCT05862623
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Jul 31, 2024
- First posted
- May 17, 2023
- Last posted
- Aug 30, 2023
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aer TherapeuticsLead sponsor
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.